论文部分内容阅读
目的探讨美罗培南在老年卒中相关性肺炎(SAP)临床治疗中的应用效果。方法选择河南大学淮河医院神经内科2012年2月—2014年2月接收的72例SAP患者作为研究对象并随机分为两组,各36例,其中对照组静脉注射头孢他啶治疗,研究组静脉注射美罗培南治疗,比较两组临床治疗效果及不良反应发生情况。结果研究组退热、咳嗽消失、湿罗音消失、白细胞恢复正常及平均住院时间均较对照组显著减少(P<0.05);两组不良反应发生率比较无显著性差异(P﹥0.05);且不良反应均轻微,不影响继续治疗,而治疗前后血常规、尿常规及肝肾功能无影响。结论美罗培南用于老年卒中相关性肺炎治疗可明显改善患者临床症状和体征,且不良反应少,安全性高,具有临床应用价值。
Objective To investigate the clinical effect of Meropenem in the treatment of senile stroke-associated pneumonia (SAP). Methods Seventy-two patients with SAP admitted to Department of Neurology, Huaihe Hospital, Henan University from February 2012 to February 2014 were randomly divided into two groups (n = 36 each), in which the control group received intravenous ceftazidime and the study group received intravenous injection of Luo Peinan treatment, the clinical efficacy of the two groups compared with the incidence of adverse reactions. Results There was no significant difference in incidence of adverse reactions between the two groups (P> 0.05). The study groups were found to have fever, cough disappearance, disappearance of wet rales, normal leucocyte recovery and average length of hospital stay (P <0.05). And adverse reactions are mild, does not affect the continued treatment, and before and after treatment of blood, urine and liver and kidney function had no effect. Conclusion Meropenem for stroke-associated pneumonia in elderly patients can significantly improve the clinical symptoms and signs of patients with less adverse reactions, high safety and clinical application.